Skip to main content

Table 5 Cox Regression analysis to determine factors associated with LTFU, Tshepang Pharmacovigilance cohort, 2004-2012

From: Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012: a cohort study

Characteristic   Univariate analysis Multivariate Analysis
   HR 95 % CI P value aHR 95 % CI P value
Age at ART ≥ 45 Ref*    Ref*   
Initiation ≥ 30 and < 45 0.77 0.50 - 1.19 0.240 0.71 0.37 - 1.37 0.310
  < 30 0.94 0.59 - 1.51 0.810 0.58 0.28 - 1.21 0.144
Partner status Present Ref*    Ref*   
  Absent 1.75 1.08 - 2.84 0.024 2.88 1.19 - 6.97 0.019
Employment Employed Ref*    Ref*   
Status Self employed 7.18 1.69 - 30.54 0.008 13.92 2.81 - 69.06 0.001
  Unemployed 1.57 1.01 - 2.44 0.045 1.75 0.86 - 3.56 0.123
Adverse events No Ref*    Ref*   
  Yes 0.49 0.34 - 0.70 <0.001 0.61 0.38 - 0.99 0.044
Baseline CD4 CD4 ≤ 200 Ref*    Ref*   
Count CD4 > 200 2.47 1.42 - 4.31 0.001 3.81 1.85 - 7.85 < 0.001
First VL level Undetectable VL Ref*    Ref*   
after ART Detectable VL 1.81 1.21 - 2.72 0.004 1.00 0.58 - 1.73 0.998
Last known CD4 CD4 ≤ 200 Ref*    Ref*   
Count CD4 > 200 0.42 0.29 - 0.60 < 0.001 0.88 0.51 - 1.53 0.651
Last known VL Undetectable VL Ref*    Ref*   
Level Detectable VL 3.20 2.20 - 4.67 < 0.001 3.60 1.98 - 6.52 < 0.001
Last known WHO Stage 1 or 2 Ref*    Ref*   
clinical stage Stage 3 or4 3.20 2.24 - 4.57 < 0.001 2.00 1.22 - 3.27 0.006
  1. *Ref - Reference category